- Home
- SRFM vs TIL Comparison
SRFM vs TIL Comparison
Compare SRFM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- TIL
- Stock Information
- Founded
- SRFM 2011
- TIL 2018
- Country
- SRFM United States
- TIL United States
- Employees
- SRFM N/A
- TIL N/A
- Industry
- SRFM Transportation Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- TIL Health Care
- Exchange
- SRFM Nasdaq
- TIL Nasdaq
- Market Cap
- SRFM 191.9M
- TIL 177.1M
- IPO Year
- SRFM 2023
- TIL 2021
- Fundamental
- Price
- SRFM $3.52
- TIL $15.44
- Analyst Decision
- SRFM Buy
- TIL Strong Buy
- Analyst Count
- SRFM 4
- TIL 5
- Target Price
- SRFM $5.75
- TIL $100.67
- AVG Volume (30 Days)
- SRFM 3.0M
- TIL 75.3K
- Earning Date
- SRFM 11-12-2025
- TIL 11-13-2025
- Dividend Yield
- SRFM N/A
- TIL N/A
- EPS Growth
- SRFM N/A
- TIL N/A
- EPS
- SRFM N/A
- TIL N/A
- Revenue
- SRFM $107,372,000.00
- TIL N/A
- Revenue This Year
- SRFM N/A
- TIL N/A
- Revenue Next Year
- SRFM $18.06
- TIL N/A
- P/E Ratio
- SRFM N/A
- TIL N/A
- Revenue Growth
- SRFM N/A
- TIL N/A
- 52 Week Low
- SRFM $1.50
- TIL $10.80
- 52 Week High
- SRFM $9.91
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- SRFM 35.19
- TIL 35.79
- Support Level
- SRFM $3.41
- TIL $18.10
- Resistance Level
- SRFM $4.09
- TIL $20.11
- Average True Range (ATR)
- SRFM 0.27
- TIL 1.29
- MACD
- SRFM -0.12
- TIL -0.28
- Stochastic Oscillator
- SRFM 6.94
- TIL 7.21
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.